Search PubMed⌕ Search

Biomedical subjects

S Khoury

Publications and source records attributed to S Khoury.

At least 73 records · Page 4Linked to original sources
PubMed1984

[Comparison of serum and prostatic levels of tobramycin].

In 19 patients with various prostatic diseases, serum and prostatic tissue levels of tobramycin were determined by bioassay and enzyme immunoassay after 1, 3 or 4 intramuscular injections of 75 mg tobramycin. The last injection was given ninety minutes prior to prostatectomy. Mean serum and prostatic tissue levels were respectively 3.55 micrograms/ml and 1.70 micrograms/g by bioassay, and 3.55 micrograms/ml and 2.37 micrograms/g by enzyme immunoassay. There was no significant difference in prostatic tissue levels between patients who received 3 or 4 drug doses and those who received one dose. Prostatic tissue levels were not significantly different in adenoma and chronic prostatitis.

Biological Assay↗
PubMed1983

[Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)].

Fifteen normal menstruating women in the early follicular phase of their menstrual cycle, fifteen patients with prolactin secreting adenomas, two patients with a suprahypophysial lesion and an hyperprolactinemia, underwent a dopamine infusion (4 micrograms/kg/mn for four hours and an orally administration of domperidone (40 mg). Prolactin rebound after the arrest of dopamine infusion and during domperidone are + 400% and + 2,300% in normal subjects. These same studies are followed by similar and reduced prolactin response in suprahypophyseal lesion and prolactinomas. Such results suggest an abnormality of central dopaminergic control and/or a primary abnormality of lactotropes in prolactinomas. In two prolactinomas the normalization of both prolactin level and prolactin responses during the same tests is in favor of a primary abnormality of adenomatous lactotrope. These data justify neuro-surgical adenomectomy.

Adenoma↗
PubMed1981

[Domperidone: a new pharmacodynamic agent for exploration of the hypophysis (author's transl)].

Domperidone is a peripheral antagonist of dopamine which does not cross the blood-brain barrier. It is administered orally in doses of 40 mg and consistently induces a rise in prolactin (delta + 2500 % at 90 minutes; surface under the curve 306,000) on condition that the mammotropic cells are in sufficient numbers and under central dopamine control. Adenomatous mammotrophs do not respond to domperidone (p less than 0.001 difference with controls). Three months after transphenoidal adenomectomy and correction of hyperprolactinaemia, there was no significantly change in the kinetics of prolactin response to the product. Some gonadotrophic hormone-producing adenomas exhibit paradoxical response of GH to L-dopa and domperidone, which disappears after surgical excision.

Benzimidazoles↗
PubMed1981

Leydig cell tumor with gynecomastia: hormonal effects of an estrogen-producing tumor.

A patient with a testicular interstitial cell tumor and gynecomastia is reported. The testicular tumor was capable of aromatizing 8.3% testosterone. Spermatic venous samples taken from the tumor-bearing side had marked elevations of 17 beta-estradiol (E2), progesterone, and 17-hydroxyprogesterone (170 HP). The progesterone to 17OHP and 17OHP to androstene-dione ratios suggested an enzymatic block of 17 alpha-hydroxylase and 17-20 lyase possibly secondary to locally produced E2. The E2 produced by the tumor appeared to suppress gonadotropin secretion. The plasma testosterone and gonadotropin levels rose within 7 days after the removal of tumor, and the gynecomastia began to decrease.

Adult↗
PubMed1980

Estramustine phosphate in the treatment of advanced prostatic cancer.

Thirty patients with advanced carcinoma of the prostate were treated with estramustine phosphate. All patients were followed up for a minimum of 9 months. Of 15 not previously treated with oestrogens 9 responded objectively and 11 subjectively. Of 15 patients whose tumours had failed to respond to at least 2 oestrogens, 3 responded objectively and 5 subjectively. Adverse effects consisted of cardiovascular complications, gynaecomastia and impotence. Gastrointestinal side effects were minimal and no hepatic, renal or marrow toxicity was seen. The criteria of assessment of response are discussed.

Estramustine↗
PubMed1980

[Scanner examination of the kidney].

On the basis of a large series of documents, the authors participate in establishment of the classification of scanner appearances of urological diseases of the kidney : peripheral or parapelvic sub-capsular cysts, carcinomas and their spread, multiple tumours but of different nature in the same kidney, angiomyolipomas, polycystic disease, renal abscess, hydated cyst, non-invasive exploration of kidneys showed to be non-functioning by I.V.U., tumours of the intrarenal excretory system, lumbar trauma, long-term surveillance of the retroperitoneal space in individuals undergoing surgery for a urological malignant renoureteric tumour. The authors suggest a new chronological arrangement of investigations in the presence of a renal mass discovered by I.V.U. Scanner has its place between echotomography and renal arteriography. Investigations may be stopped at renal echotomography when this examination offers definite evidence of the fluid nature of the mass. Solid or doubtful nature of the mass necessitates the use of a scanner examination.

Abscess↗